US equities
|
SPCX
$167.46
▲+5.34%
NVDA
$236.34
▲+1.02%
MU
$1,064.90
▼-0.93%
TSLA
$378.34
▲+2.09%
MSFT
$525.78
▲+1.60%
SNDK
$1,708.61
▼-0.66%
INTC
$117.43
▼-1.59%
META
$744.42
▲+2.24%
SPCX
$167.46
▲+5.34%
NVDA
$236.34
▲+1.02%
MU
$1,064.90
▼-0.93%
TSLA
$378.34
▲+2.09%
MSFT
$525.78
▲+1.60%
SNDK
$1,708.61
▼-0.66%
INTC
$117.43
▼-1.59%
META
$744.42
▲+2.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Amylyx Pharmaceuticals, Inc. - Common Stock
(NQ:
AMLX
)
27.70
-0.09 (-0.32%)
Delayed Quote
Updated: 12:28 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amylyx Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
May 07, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
May 06, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia
May 05, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
April 30, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Reports Narrower-Than-Expected Q4 Loss, Focus Remains on Key 2026 Data
↗
March 03, 2026
Via
Chartmill
Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
April 08, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
March 24, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx (AMLX) Q4 2025 Earnings Call Transcript
↗
March 03, 2026
Amylyx (AMLX) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
March 03, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences
February 26, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million
↗
February 25, 2026
This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs.
Via
The Motley Fool
Topics
Regulatory Compliance
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
↗
February 25, 2026
RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials.
Via
The Motley Fool
Topics
Regulatory Compliance
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst
↗
February 25, 2026
This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology.
Via
The Motley Fool
Topics
Regulatory Compliance
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
February 24, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Co-Chief Executive Sells AMLX 138K Shares for $1.9 Million
↗
February 01, 2026
A Co-CEO of a leading neurotherapeutics developer reported significant insider selling amid a year of standout stock performance. But the sale is not what it seems.
Via
The Motley Fool
Topics
Initial Public Offering
Regulatory Compliance
Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S
January 08, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?
↗
December 09, 2025
A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters.
Via
The Motley Fool
Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow?
↗
December 09, 2025
Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down.
Via
The Motley Fool
Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets
↗
December 09, 2025
A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story.
Via
The Motley Fool
Topics
Regulatory Compliance
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial
December 05, 2025
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance?
↗
December 03, 2025
One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.
Via
The Motley Fool
Topics
Regulatory Compliance
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead
↗
November 17, 2025
A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm.
Via
The Motley Fool
Topics
Regulatory Compliance
This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch
↗
November 17, 2025
This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization.
Via
The Motley Fool
Topics
Regulatory Compliance
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying
↗
November 17, 2025
A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data.
Via
The Motley Fool
Topics
Regulatory Compliance
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover
↗
November 17, 2025
One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.
Via
The Motley Fool
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX
November 13, 2025
From
The Rosen Law Firm, P.A.
Via
Business Wire
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX
November 11, 2025
From
Rosen Law Firm
Via
Business Wire
Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Avantor, Inc. (NYSE: AVTR); Humana Inc. (NYSE: HUM); and Maison Solutions Inc. (NASDAQ: MSS): Grabar Law Office Investigates Claims on Your Behalf
November 06, 2025
From
Grabar Law Office
Via
GlobeNewswire
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Narrows Q3 2025 Loss, Bolsters Cash Runway to 2028
↗
November 06, 2025
Amylyx Pharmaceuticals posts a narrower-than-expected Q3 2025 loss. The company bolsters its cash position, extending its runway into 2028 to fund its clinical pipeline.
Via
Chartmill
Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results
November 06, 2025
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
